Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  PCAS    PCA   FR0000053514

PCAS (PCA)

Delayed Quote. Delayed  - 08/26 05:35:20 pm
9.8 EUR   +0.51%
07/19 PCAS : Net sales for the 1st half of 2016
07/19 PCAS : SUSTAINED GROWTH IN NET SALES FOR THE 1st HALF OF 2016
07/13 PCAS : signs a global distribution agreement with MilliporeSigma
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

PCAS : Clinigen and PCAS sign long-term supply agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/06/2012 | 09:53am CEST
PRESS RELEASE Clinigen and PCAS sign long?term supply agreement for the production of Foscavir Active Pharmaceutical Ingredient (API) 5th January 2012 Burton?on?Trent, UK, and Longjumeau, France ?? Clinigen Healthcare, the products division of Clinigen Group, has signed a long?term global supply agreement with PCAS, a leading active pharmaceutical ingredient (API) manufacturer, for the production of the Foscavir drug substance.

Under the agreement, PCAS will be responsible for manufacturing foscarnet sodium hexahydrate, the API contained in Clinigen's Foscavir, while Clinigen will leverage its own infrastructure and global network of partners to supply the medicine to hospitals worldwide.
Clinigen holds marketing authorizations to sell Foscavir as a treatment for HIV/AIDS?related cytomegalovirus (CMV) infections and herpes in 16 markets, as well as in bone marrow transplantation in Japan. Clinigen is working with medicines regulatory agencies to secure licenses to market Foscavir in additional markets, including the US in Q1 2012.
Anton Jenkins, Chief Operating Officer of Clinigen Healthcare, commented: "PCAS has an impeccable track record in the area of API manufacturing, with strong technical capabilities and robust compliance systems, making the company an ideal partner for Clinigen. We are confident that PCAS and Clinigen will together ensure the continued availability of Foscavir wherever it is needed. Our agreement underlines Clinigen Group's mission to get the right drug to the right patient at the right time."
Didier Combis, Head of the Exclusive Synthesis business unit at PCAS, said:
"We are delighted to be working with Clinigen and its team of experienced managers. The company's streamlined structure allows for very short response times, a key requirement in the low?volume, specialist?supply drugs business. This agreement makes a perfect fit for PCAS. We will rely on our dedicated site in France for the production of starting material and our world?class facilities in Finland for the manufacture of injectable APIs."

About Clinigen Healthcare

Clinigen Healthcare is part of Clinigen Group, a fast?growing specialty pharmaceutical and pharma services business formed by merger in 2010. Clinigen Healthcare acquires or in?licenses mature or end?of?lifecycle products for development and commercialization in hospitals. Clinigen Healthcare's core therapeutic areas include oncology, leukemia, hematology, transplantation, virology, pain management and critical care. The company also looks to acquire products that it can develop and commercialize in orphan indications.

Clinigen Group is headquartered in Burton?on?Trent, UK, with offices in Philadelphia, US, and Tokyo, Japan. For more information visit: www.clinigengroup.com.

About PCAS

PCAS is a Euronext compartiment C?listed company specializing in the production of specialty chemicals and active pharmaceutical ingredients for life sciences customers. It develops, manufactures and markets complex molecules and competitive industrial
solutions for the global healthcare, cosmetic and material science industries, with a focus on
quality, innovation, safety and sustainability. For more information visit: www.pcas.com.

About Foscavir

Foscavir (foscarnet sodium) is licensed to treat cytomegalovirus (CMV) retinitis in HIV patients and acyclovir?resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromized patients in: Australia, Belgium, France, Germany, Hungary, Israel, Italy, Japan, Luxembourg, Mexico, the Netherlands, New Zealand, Singapore, Spain, Switzerland and the UK. In July 2011, the Japanese Ministry of Health Labor and Welfare (MHLW) approved Foscavir for the treatment of CMV in hematopoietic stem cell transplant patients.
For more information visit:
www.medicines.org.uk/EMC/company/3129/Clinigen%20Healthcare%20Ltd

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PCAS
07/19 PCAS : Net sales for the 1st half of 2016
07/19 PCAS : SUSTAINED GROWTH IN NET SALES FOR THE 1st HALF OF 2016
07/13 PCAS : signs a global distribution agreement with MilliporeSigma
07/13 PCAS : sign a global distribution agreement with MilliporeSigma
07/12 PCAS : Signs a global distribution agreement with MilliporeSigma, enabling a bet..
06/28 PCAS : Inauguration of a new workshop at the couterne site
06/28 PCAS : Inauguration of a new workshop at the couterne site
06/22 PCAS : confirms its PME SME eligibility
06/07 PCAS : Collaboration Syngenta
06/07 PCAS : Syngenta Collaboration
More news
Sector news : Pharmaceuticals - NEC
12:53a Stada shareholder AOC pushes through board reshuffle
12:43a ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26 MUDDY WATERS SAYS ST. JUDE SHARES CO : Cnbc
08/26DJALERE : Sues Abbott to Force Merger -- 2nd Update
More sector news : Pharmaceuticals - NEC
Advertisement
Financials (€)
Sales 2016 196 M
EBIT 2016 19,0 M
Net income 2016 11,0 M
Debt 2016 31,0 M
Yield 2016 1,22%
P/E ratio 2016 11,95
P/E ratio 2017 10,21
EV / Sales 2016 0,92x
EV / Sales 2017 0,85x
Capitalization 148 M
More Financials
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Full-screen chart
Technical analysis trends PCAS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 11,0 €
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Vincent Touraille CEO & Financial Communications Contact
Christian Moretti Chairman
Pierre Schreiner Deputy Chief Executive Officer-Operations
Eric Moissenot Deputy CEO-Finance & Administration
Gérard Guillamot Director-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PCAS22.33%166
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-11.47%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-9.62%210 234
ASTRAZENECA PLC7.33%173 797
More Results